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a b s t r a c t
Both increased inflammation and reduced neurogenesis have been associated with the pathophysiology
of major depression. We have previously described how interleukin-1 (IL-1) b, a pro-inflammatory cyto-
kine increased in depressed patients, decreases neurogenesis in human hippocampal progenitor cells.
Here, using the same human in vitro model, we show how omega-3 (x-3) polyunsaturated fatty acids
and conventional antidepressants reverse this reduction in neurogenesis, while differentially affecting
the kynurenine pathway. We allowed neural cells to proliferate for 3 days and further differentiate for
7 days in the presence of IL-1b (10 ng/ml) and either the selective serotonin reuptake inhibitor sertraline
(1 mM), the serotonin and norepinephrine reuptake inhibitor venlafaxine (1 mM), or the x-3 fatty acids
eicosapentaenoic acid (EPA, 10 mM) or docosahexaenoic acid (DHA, 10 mM). Co-incubation with each of
these compounds reversed the IL-1b-induced reduction in neurogenesis (DCX- and MAP2-positive neu-
rons), indicative of a protective effect. Moreover, EPA and DHA also reversed the IL-1b-induced increase
in kynurenine, as well as mRNA levels of indolamine-2,3-dioxygenase (IDO); while DHA and sertraline
reverted the IL-1b-induced increase in quinolinic acid and mRNA levels of kynurenine 3-
monooxygenase (KMO). Our results show common effects of monoaminergic antidepressants and x-3
fatty acids on the reduction of neurogenesis caused by IL-1b, but acting through both common and dif-
ferent kynurenine pathway-related mechanisms. Further characterization of their individual properties
will be of benefit towards improving a future personalized medicine approach.
Crown Copyright  2017 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Hippocampal neurogenesis has been widely associated with
depression: reduced levels have been reported in depressed
patients as well as in animal models of depression (Boldrini
et al., 2009; Kempermann et al., 2008), and increasing its levels
appears sufficient to reduce depressive-like behaviours (Hill
et al., 2015). Several factors can regulate neurogenesis: it can be
stimulated by antidepressant drugs (Warner-Schmidt and
Duman, 2006; Sahay and Hen, 2007; Malberg and Blendy, 2005)
and negatively affected by pro-inflammatory cytokines such as
interleukin-1 (IL-1) b (Goshen et al., 2008; Koo and Duman,
2008; Kuzumaki et al., 2010). This cytokine is of importance, as
increased levels have been shown in peripheral blood and cere-
brospinal fluid of depressed patients (Capuron and Miller, 2004;
Howren et al., 2009; Maes et al., 2009; Miller et al., 2009;
Mossner et al., 2007; Raison et al., 2006; Schiepers et al., 2005).
Notably, higher levels of IL-1b are known to affect synaptic trans-
mission, causing impairments of learning and memory (Yirmiya
and Goshen, 2011).
One of the underlying mechanisms by which IL-1b and other
pro-inflammatory cytokines can affect neurogenesis is through
alterations of the kynurenine pathway (see Fig. 1 for a simplified
description). This pathway starts from the essential amino acid
tryptophan and can generate the neurotoxic quinolinic acid
(QUIN), a putative NMDA receptor antagonist (Schwarcz et al.,
2012), whose accumulation can be prevented by production of
picolinic acid (PIC), a potentially neuroprotective metabolite. Dys-
regulation in levels of several kynurenine pathway metabolites has
been described in depression and other psychiatric disorders. For
example, increased levels of QUIN have been detected in animal
http://dx.doi.org/10.1016/j.bbi.2017.05.006
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models of depressive-like behavior (Fischer et al., 2015), in hepati-
tis C patients with depression induced by IFN-a (Raison et al.,
2010) and in the cerebrospinal fluid (CSF) of suicide attempters
(Erhardt et al., 2013), who have also been shown to have reduced
PIC and a decreased PIC/QUIN ratio in both CSF and blood
(Brundin et al., 2016). Similarly, increased levels of kynurenine
have been detected in depression induced by IFN-a (Capuron
et al., 2003) and in the hippocampus of patients with Alzheimer’s
disease (Guillemin et al., 2005), while the peripheral ratio of
kynurenic acid/QUIN ratio has been shown to be reduced in
depressed individuals (Meier et al., 2016; Savitz et al., 2015).
Considering the regulatory effects of these metabolites, the role
of enzymes of the pathway that control their production is of sig-
nificant interest. For example, inhibition of IDO, the first enzyme of
the pathway, reduced the depression-like behavior induced by
inflammation via peripheral (O’Connor et al., 2009) or intracerebral
(Dobos et al., 2012) administration of lipopolysaccharide (LPS) in
mice. Furthermore, inhibition of KMO reversed cognitive and
motor deficits measured in neurodegeneration, using mouse mod-
els of Alzheimer’s disease and Huntington’s disease (Zwilling et al.,
2011). Interestingly, KMO-deficient mice have been shown to be
protected from inflammation-induced depressive-like behavior
(Heisler and O’Connor, 2015; Parrott et al., 2016).
Our previous research has shown that IL-1b decreases neuroge-
nesis while increasing levels of expression of all neurotoxicity-
associated enzymes of the kynurenine pathway. This effect was
partially reversed by KMO inhibition, suggesting that activation
of the kynurenine pathway is indeed contributing to this
cytokine-induced reduction of neurogenesis (Zunszain et al.,
2012). Using the same in vitro model, we have also described
how reduced neurogenesis induced by glucocorticoids is reversed
by the SSRI sertraline (Anacker et al., 2011). Considering that IL-
1b levels decrease in patients upon antidepressant treatment
(Hannestad et al., 2011), we here explore the possibility that a reg-
ulation of neurogenesis in inflammatory conditions may be a com-
mon underlying pathway of antidepressant action. We investigate
two antidepressants, the SSRI sertraline and the SNRI venlafaxine,
as well as the two principal x-3 polyunsaturated fatty acids com-
ponents of fish oils, eicosapentanoic acid (EPA) and docosahex-
anoic acid (DHA), which have been associated with the
pathogenesis and treatment of depression (Su et al., 2014; Su,
2012, 2009; Lin et al., 2012, 2010; Lu et al., 2010). We have recently
shown that these four compounds have different immune-
modulating properties upon co-treatment with IL-1b: while all
were associated with a corresponding decrease in the NF-kB acti-
vation caused by IL-1b alone, venlafaxine and EPA showed mostly
anti-inflammatory properties but sertraline and DHA displayed
mostly pro-inflammatory properties (Horowitz et al., 2015). In
addition to looking at their effects on neurogenesis in the presence
of an inflammatory insult, we here extend the study of their prop-
erties, evaluating additionally whether they regulate the metabo-
lites and enzymes of the kynurenine pathway.
2. Materials and methods
2.1. Cell culture
All experiments were performed with the multipotent human
hippocampal progenitor cell line HPC0A07/03C provided by
ReNeuron (Surrey, UK). Cells were grown in reduced modified
media consisting of Dulbecco’s Modified Eagle’s Media/F12
(DMEM:F12, Invitrogen, Paisley, UK) supplemented with 0.03%
human albumin (Baxter Healthcare, Compton, UK), 100 mg/mL
human apo-transferrin, 16.2 mg/mL human putrescine diHCl, 5 mg/
mL human recombinant insulin, 60 ng/mL progesterone, 2 mM L-
glutamine and 40 ng/mL sodium selenite. To maintain prolifera-
tion, 10 ng/mL human basic fibroblast growth factor (bFGF),
20 ng/mL human epidermal growth factor (EGF) and 100 nM 4-
hydroxytamoxifen (4-OHT) were added. Cells were grown in
75 cm2 filtered cap culture flasks (Nunclon, Roskilde, Denmark)
at 37 C in 5% CO2 and regularly passaged at 80% confluence, until
being transferred to plates for the differentiation experiments.
2.2. Assays with antidepressants and x-3 fatty acids
To assess whether antidepressants and x-3 fatty acids could
abrogate changes in neuronal differentiation caused by IL-1b expo-
sure, HPC0A07/03C cells were plated on 96 well plates (Nunclon)
at a density of 1000 cells per well. Cells were cultured in the pres-
ence of EGF, bFGF and 4-OHT and treated with IL-1b (10 ng/mL)
either alone or in combination with the antidepressant venlafaxine
(1 lM) or sertraline (1 lM), or one of the x-3 fatty acids, EPA
(10 lM) or DHA (10 lM). Antidepressants and x-3 fatty acids were
dissolved in EtOH. All treatments had the same vehicle, including
Fig. 1. Simplified kynurenine pathway of tryptophan metabolism. ACMSD: aminocarboxymuconate semialdehyde decarboxylase, IDO: indolamine-2,3-dioxygenase, KAT:
kynurenine aminotransferase, KMO: kynurenine 3-monooxygenase or kynurenine 3-hydroxylase, KYNU: kynureninase.
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0.1% ethanol, to exclude the possibility of any differences observed
being the consequence of differing concentrations of solvents.
Treatment conditions and doses were chosen as described in our
previous work (Horowitz et al., 2015). After 3 days, cell-
conditioned media was collected and stored at 80 C for subse-
quent measurement of kynurenine metabolites, cells were washed
and treatment with the cytokine and each of the four compounds
was repeated in media without growth factors and 4-OHT for 7
subsequent days. At the end of the total incubation time (10 days),
cells were fixed with 4% PFA to be further processed by immunocy-
tochemistry. Treatment with the cytokine and all drugs was also
conducted in 6 well plates to extract RNA after 24 h in proliferation
media, in order to investigate changes in gene expression.
2.3. Immunocytochemistry
Neuronal differentiation and maturation were assessed by dou-
blecortin (DCX) and microtubulin-associated protein-2 (MAP2)
immunocytochemistry. Briefly, PFA-fixed cells were incubated in
blocking solution (5% normal donkey serum, Scientific Laboratory
Supplies Ltd, Nottingham, UK) in PBS containing 0.3% Triton-X for
2 h at room temperature, and with primary antibodies [rabbit
anti-DCX, 1:500; mouse anti-MAP2 (HM), 1:500, Abcam, Cam-
bridge, UK] at 4 C overnight. Specificity of the MAP2 (HM) anti-
body for mature neurons in our cell culture was previously
confirmed (Anacker et al., 2011). Cells were incubated sequentially
in blocking solution for 30 min, secondary antibodies (Alexa 488
donkey anti-rabbit; 1:1000; Alexa donkey 555 anti-mouse,
1:1000, Invitrogen) for 1 h, and Hoechst 33342 dye (0.01 mg/ml,
Invitrogen) for 5 min at room temperature. The number of DCX-
and MAP2-positive cells over total Hoechst 33342 positive cells
was counted with an automated approach using CellInsight NXT
High Content Screening (HCS) Platform (ThermoScientific). Nega-
tive controls were incubated with unspecific mouse IgGs (1:500,
control for MAP2), rabbit IgGs (1:500, control for DCX) in place of
the specific primary antibody.
2.4. RNA isolation and cDNA synthesis
RNA was isolated using the RNeasy Micro Kit (Qiagen, Crawley,
UK) following the manufacturer’s instructions and samples were
kept frozen at 80 C until further use. RNA quantity and quality
were assessed by evaluation of the A260/280 and A260/230 ratios
using a Nanodrop spectrometer (NanoDrop Technologies, Wilm-
ington, DE, USA). Superscript III enzyme (Invitrogen, Carlsbad, CA,
USA) was used to reverse transcribe 1 mg total RNA as previously
described (Anacker et al., 2011).
2.5. Quantitative Real Time PCR (qPCR) analyses
qPCR was performed using Predesigned TaqMan Gene Expres-
sion Assay probes (Life Technologies) with TaqMan Universal PCR
Master Mix with UNG (Life Technologies), using Chromo 4 DNA
instrument from BioRad. The expression of target genes indolea-
mine 2,3-dioxygenase (IDO), kynurenine 3-monooxygenase
(KMO), kynureninase (KYNU) and aminocarboxymuconate semi-
aldehyde decarboxylase (ACMSD) was normalized to the expres-
sion levels of beta actin (ACTB) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as references. The relative expression
levels of target genes detected were calculated using the Pfaffl
method (Bustin et al., 2005), with data normalized to the geometric
mean of the housekeeping genes and expressed as fold change
compared with the control sample. Three independent experi-
ments were conducted on independent cultures, and each sample
was tested in duplicate.
2.6. Sample preparation for metabolite analysis
After 3 days of proliferation, before media was changed to allow
differentiation for 7 subsequent days, the cell media from each
experimental condition was removed and centrifuged
(2000  rpm, 5 min) to pellet and remove dead cells. This super-
natant was then assayed for metabolites of the kynurenine path-
way, by adding an equal volume of ice cold 1 M perchloric acid
(HClO4) fortified with deuterated tryptophan as internal standard
(final concentration 1 mM); samples were centrifuged (15,000g,
10 min at 4 C) and the supernatants were collected for direct
injection into the LC-MS/MS.
2.7. Liquid chromatography
The analyses of tryptophan (Trp), kynurenine (KYN), anthranilic
acid (ANA), picolinic acid (PIC) and quinolinic acid (QUIN) were
performed using an Agilent HP 1200 liquid chromatograph (Agi-
lent, Milan, Italy) consisting of a binary pump, an autosampler
and a thermostated column compartment. Chromatographic sepa-
rations were carried out using a Discovery HS-F5 column
(150  4.6 mm, 5 mm, Supelco, Milan, Italy) using 0.1% formic acid
in water and acetonitrile (ACN) as mobile phase. The HPLC analyses
were carried out using a linear elution profile of 15 min from 5% to
90% of ACN. The column was washed with 90% ACN for 3.5 min,
then equilibrated for 5 min with 5% ACN. The flow rate was
0.5 mL/min. The injection volume was 40 mL. An Agilent 6410 triple
quadrupole-mass spectrometer with an electrospray ion source
operating in positive mode was used for detection. The optimized
source parameters for MS analysis were: drying gas temperature
350 C and gas flow 12 L/min, nebulizer gas flow pressure 35 psi
and capillary voltage 4500 V. The optimized fragmentor voltage
was 66 V and the collision energies were 4, 4, 8, 8, 8, 24 and 8 eV
for Trp, KYN, ANA, PIC, QUIN and internal standard, respectively.
The SRM pairs were 205–>188 (118), 209–>192 (94), 138–>120
(65), 124–>106 (51) and 168–>78 (114) and 210–>192 for Trp,
KYN, ANA, PIC, QUIN and internal standard, respectively. The cali-
bration curves were constructed using seven calibration standards
and were linear over the concentration range of 0.001–2.000 mM
for ANA, 0.01–5.00 mM for KYN, PIC and QUIN and 0.1–20 mM for
TRP, with a correlation coefficient (r2)  0.9983 for all analytes.
The limit of detection at a signal-to-noise ratio of 3:1 and lower
limit of quantitation were 0.0005 and 0.0010 mM for ANA; 0.005
and 0.010 mM for KYN, PIC and QUIN; 0.05 and 0.1 mM for TRP.
2.8. Drugs and reagents
All drugs and reagents were purchased from Sigma–Aldrich (St
Louis, MO, USA), unless otherwise stated. IL-1b, EGF and bFGF were
purchased from Peprotech (London, UK).
2.9. Statistical analysis
Data are presented as mean ± SEM. All statistical analyses were
performed with GraphPad Prism 7 on four independent biological
replicates. One-Way ANOVA with Bonferroni’s post hoc test was
used for multiple comparisons among treatment groups. Student’s
t-test was used to compare means of two independent treatment
groups; p-values of <0.05 were considered significant.
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3. Results
3.1. Antidepressants and x-3 fatty acids prevent the IL-1b-induced
reduction of neurogenesis
Treatment of cells with IL-1b (10 ng/mL) for three days of pro-
liferation followed by seven days of differentiation reduced the
percentage of DCX-positive and MAP2-positive and cells by 28%
and 40%, respectively (Fig. 2a). These changes were similar to those
we have previously reported (Zunszain et al., 2012). To establish
whether the x-3 fatty acids EPA and DHA, and the monoaminergic
antidepressants venlafaxine and sertraline, were able to reverse
these detrimental effects of IL-1b cells were co-incubated with
the cytokine and each of the compounds at doses previously estab-
lished (Horowitz et al., 2015). Co-incubation of cells with IL-1b and
either EPA (10 lM), DHA (10 lM), sertraline (1 lM) or venlafaxine
(1 lM) reversed the decrease in the percentage of DCX-positive
neurons caused by IL-1b to +50%, +70%, +53% and +53%, respec-
tively (Fig. 2b). Of note, individual treatment with either x-3 fatty
acids or antidepressants did not affect the number of DCX-positive
cells (data not shown). Similarly, the reduction of MAP2-positive
cells caused by IL-1b was reversed upon co-incubation with all
drugs to +94% with EPA, +88% with DHA, +79% with sertraline
and +67% with venlafaxine (Fig. 2c). Treatment withx-3 fatty acids
alone did not affect the number of MAP2-positive cells. In accor-
dance with our previous data (Anacker et al., 2011), sertraline sig-
nificantly increased the number of MAP2-positive cells by +7%,
when compared with control (data not shown). Venlafaxine also
enhanced MAP2-positive staining by +8% (data not shown).
Although antidepressants alone were able to affect the number of
MAP2-positive cells, this effect was much lower than what we
report upon co-incubation with IL-1b and both antidepressants
(+79% for sertraline and +67% for venlafaxine). Therefore, these
findings are consistent with the notion that antidepressant com-
pounds may play an important role in reversing the negative
effects of inflammation on neurogenesis.
3.2. IL-1b treatment modulates levels of metabolites and enzymes of
the kynurenine pathway
Treatment of cells with IL-1b affected the production of
metabolites and enzymes of the kynurenine pathway. Specifically,
IL-1b increased kynurenine levels detected in the supernatant of
proliferating cells exposed to the cytokine for 3 days by 96%, and
increased levels of quinolinic acid by 208%, compared with
vehicle-treated cells, and decreased levels of anthranilic acid by
28%. No significant changes were observed for either tryptophan
or picolinic acid in the conditioned media (Fig. 3a). Treatment with
IL-1b increased levels of expression of enzymes involved in the
production of quinolinic acid, namely IDO, KMO and KYNU, with
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Fig. 2. Monoaminergic antidepressants and x-3 fatty acids reverse the IL-b-induced reduction of human hippocampal cells neurogenesis. Treatment with IL-1b decrease
DCX-positive cells (immature neuronal phenotype), and MAP2 positive cells (mature neuronal phenotype) (a). Treatment with EPA, DHA, sertraline or venlafaxine reverse the
IL-1b-induced decrease in DCX positive cells (b), and MAP2-positive cells (c); ****p < 0.0001.
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fold changes of 15, 13 and 9, respectively, in line with what we
have shown before (Zunszain et al., 2012). We here extended our
evaluation of enzymes measuring ACMSD, which is responsible
for limiting the formation of quinolinic acid by production of the
neuroprotective metabolite picolinic acid. Treatment with the
cytokine caused a 3-fold increase in levels of expression of this
enzyme (Fig. 3b).
3.3. Antidepressants and x-3 fatty acids differentially modulate levels
of metabolites of the kynurenine pathway
To investigate whether the ability of antidepressants and x-3
fatty acids to counteract the negative effects of IL-1b on neurogen-
esis involved effects on the kynurenine pathway, we first measured
their action on metabolites. No compound significantly modulated
the amount of tryptophan, highly present in the culture media,
with respect to IL-1b exposed cells (data not shown), however
the increase in levels of kynurenine caused by the cytokine was
partially reverted by co-incubation with both x-3 fatty acids (from
96% with IL-1b alone to 47% when co-incubated with EPA and 41%
with DHA) (Fig. 4a). On the contrary, the decrease in anthranilic
acid was abrogated by co-treatment with sertraline (from 28%
to +12%) (Fig. 4b). Similarly, DHA and sertraline partially abrogated
the rise in quinolinic acid caused by the cytokine (from +208% with
IL-1b alone to +45% when co-incubated with DHA and +49% with
sertraline), whereas EPA and venlafaxine showed a non-
significant reduction in quinolinic acid levels (Fig. 4c). There was
no significant effect of either x-3 fatty acids or antidepressants
on levels of picolinic acid (Fig. 4d).
3.4. Antidepressants and x-3 fatty acids differentially regulate
enzymes of the kynurenine pathway
Both antidepressants and x-3 fatty acids altered the changes in
mRNA levels of all the four enzymes of the kynurenine pathway
that had been modulated by IL-1b exposure. EPA, DHA, sertraline
and venlafaxine decreased the upregulation of IDO expression by
36%, 81%, 44% and 38% respectively, when compared with IL-1b
alone (Fig. 5a). Co-treatment with DHA, sertraline and venlafaxine
decreased the upregulation of KMO caused by IL-1b by 69%, 72%
and 44%, respectively (Fig. 5b). Surprisingly, co-incubation with
DHA caused a further 108% upregulation of KYNU when compared
with IL-1b alone (Fig. 5c). Finally, only sertraline and venlafaxine
reduced the increased in ACMSD caused by the cytokine, with
changes of 44% and 71%, respectively (Fig. 5d).
4. Discussion
Our results show that EPA, DHA, sertraline and venlafaxine
counteract the detrimental effects of IL-1b on our in vitro model
of human hippocampal neurogenesis.
EPA, DHA, sertraline and venlafaxine lessened the reduction in
DCX-positive neuroblasts and MAP2-positive neurons caused by
IL-1b. This evidence that monoaminergic antidepressants and x-
3 fatty acids can reverse the anti-neurogenic effects of a pro-
inflammatory cytokine on human hippocampal cells is of relevance
given the importance attributed to immune dysfunctions in the
pathogenesis of depression. Direct exposure to IL-1b or to its
inducers, including LPS and IFN-a, has been shown to suppress
hippocampal neurogenesis, along with the development of
depressive-like symptoms in animal models (Goshen et al., 2008;
Koo and Duman, 2008; Ekdahl et al., 2009; Monje et al., 2003;
Kaneko et al., 2006). Nonetheless, despite these observations and
work demonstrating that IL-1b is integral to the anhedonic and
anti-neurogenic effects of stress (Koo and Duman, 2008), most
evaluations of the protective effect of antidepressants in both ani-
mal and cellular experiments have modeled depression using
stress paradigms or glucocorticoid exposure to simulate stressors.
As such, chronic treatment with venlafaxine reversed the decrease
in neurogenesis caused by chronic mild stress in mice (Zhang et al.,
2015). Similarly, the suppressive effects of corticosterone on adult
rat hippocampal cell proliferation were restored by paroxetine,
another SSRI (Qiu et al., 2007). Additionally, we have shown that
sertraline was able to restore the reductions of human hippocam-
pal neurogenesis caused by in vitro treatment with dexamethasone
in the same cellular model used for the present paper (Anacker
et al., 2011). Only a few studies have used inflammatory models,
aiming to efficiently mimic stress-related effects. Pre-treatment
of human-like neuronal cells with trazodone, a tetracyclic antide-
pressant, completely reversed the decrease in cell viability caused
by LPS and TNF-a (Daniele et al., 2015). Likewise, sertraline pro-
tected fetal rat hippocampal stem cells against LPS-induced cellu-
lar damage (Peng et al., 2012).
Inflammation has been thought to affect neurogenesis via sev-
eral potential pathways: by activating the hypothalamic pituitary
axis (HPA) axis to release cortisol and in turn reducing neurogene-
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Fig. 3. IL-1b modulates the production of metabolites and enzymes of the kynurenine pathway. Treatment with IL-1b affected the kynurenine pathway by (a) increasing
levels of kynurenine and quinolinic acid and decreasing levels of anthranilic acid released into the supernatant, and (b) up-regulating the expression of IDO, KMO, KYNU and
ACMSD; *p < 0.05, **p < 0.01, ****p < 0.0001.
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sis; by affecting glial cell function, regulating the production of
neurotrophic factors; and by direct effects on neural progenitor
cells (Song and Wang, 2011). The present in vitro study excludes
systemic effects such as changes to the HPA axis, so it allows for
the examination of direct effects upon progenitor cells. DHA and
sertraline reversed the effect of IL-1b on reducing neurogenesis
while also decreasing the production of quinolinic acid. At the
same time, they caused a down-regulation of KMO mRNA expres-
sion. Hence, the ability of these compounds to block stimulation of
quinolinic acid production or release induced by IL-1b may be the
mechanism by which they block the cytokine-induced reduction in
neurogenesis. Surprisingly, ACMSD, known to enhance the produc-
tion of the neuroprotective picolinic acid, was significantly upreg-
ulated by IL-1b but also by co-treatment with IL-1b and EPA or
DHA, perhaps suggesting the inductions of a counteracting mecha-
nisms against the increase in quinolinic acid previously reported.
However, the levels of the picolinic acid were not affected in our
experiments. This might suggest that either the increase in ACMSD
was not strong enough to induce an effect on the metabolite level,
or that perhaps a change in ACMSD gene expression requires a
longer time to modulate levels of picolinic acid. While activation
of the kynurenine pathway can lead to a reduction in serotonin,
the behavioral and neural effects observed upon inflammatory
insults are believed to be primarily dependent on the formation
of neurotoxic metabolites (O’Connor et al., 2009; Dantzer et al.,
2011). In particular, quinolinic acid can increase neurotoxicity by
various pathways, most notably by over-activation of NMDA
receptors and increasing cytosolic calcium ions, leading to mito-
chondrial dysfunction, cytochrome c release, ATP exhaustion, free
radical formation and oxidative damage (Perez-De La Cruz et al.,
2012; Guillemin, 2012). Studies support the role of antidepressants
acting on kynurenine metabolites, though they present a mixed
picture. Evaluations in humans have shown that the reduced
kynurenic acid/kynurenine neuroprotective ratio observed in
depressed patients increased significantly following successful
treatment with monoaminergic antidepressants (Myint et al.,
2007). Similarly, treatment of patients with escitalopram showed
a reduction of their initially elevated 3-hydroxykynurenine and
quinolinic acid levels (Halaris et al., 2015). However, no effect of
monoaminergic antidepressants was observed on levels of metabo-
lites secreted by blood from depressed patients stimulated in vitro
by LPS (Krause et al., 2012). Likewise, evaluations in animals have
shown that imipramine reduced the initially elevated kynurenine/
tryptophan ratio in the hippocampus of rats exposed to LPS or
chronic mild stress (Elgarf et al., 2014), but caused no metabolite
changes in a related study where the depression-like behavior
was induced by IFN-a (Fischer et al., 2015). The regulation of
kynurenine enzymes has also been measured: fluoxetine had no
effect on KMOmRNA levels when used to prevent the development
of depressive-like behavior in a mouse model of cancer related fati-
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Fig. 4. Antidepressants and x-3 fatty acids modulate changes of kynurenine pathway metabolites caused by IL-1b treatment. Co-treatment of cells with IL-1b and x-3 fatty
acids partially abrogated the increase in kynurenine caused by the cytokine (a). Co-treatment with sertraline fully reverted the decrease in levels of ANA caused by IL-1b (b).
Co-incubation with DHA and sertraline partially reverted the increase in QUIN levels caused by IL-1b (c). No significant changes in PIC were observed by any co-incubation
(d); *p < 0.05, **p < 0.001.
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gue (Norden et al., 2015), while agomelatine, a melatonergic
antidepressant, reversed the LPS-dependent increase in KMO
expression in the hippocampus of rats (Molteni et al., 2013).
Though conflicting, these studies are encouraging and support
the notion that metabolites and enzymes of the kynurenine path-
way are potential significant targets for therapeutic intervention.
Interestingly, a recent study demonstrated that both EPA and
DHA could increase neuronal differentiation in rat neural progeni-
tor cells, but seemed to do so by alternative mechanisms, acting on
different regulating genes to induce cell cycle arrest and neuronal
differentiation (Katakura et al., 2013). Further investigation of the
effect of these fatty acids, as well as a study of the action of sertra-
line and venlafaxine on cell cycle genes would be instructive.
Our findings are particularly relevant in understanding some of
the clinical evidence related to the use of fish oils, and support pre-
vious evidence showing a positive effect of treatment with fatty
acids on neuroinflammation, particularly in the context of depres-
sion (Mingam et al., 2008; Delpech et al., 2015; Labrousse et al.,
2012; Larrieu et al., 2014; Bazinet and Laye, 2014; Orr et al.,
2013; Lotrich et al., 2013; Kiecolt-Glaser et al., 2007; Freeman
and Rapaport, 2011; Mocking et al., 2017). Recent meta-analyses
suggested that EPA has better antidepressant effects than DHA in
combination with antidepressant medications (Mocking et al.,
2016; Grosso et al., 2014). Indeed, the clinical trials recruiting
depressed patients taking antidepressant agents as a combination
showed that either DHA is ineffective (Grenyer et al., 2007;
Silvers et al., 2005) or EPA is more effective than DHA
(Mozaffari-Khosravi et al., 2013). In addition, it has been reported
that the combined effect of higher dose of EPA with lower dose
of DHA was effective in reducing depressive symptoms in depres-
sion (Rondanelli et al., 2010; Rizzo et al., 2012) whereas the oppo-
site combination (lower EPA and higher DHA) was ineffective
(Silvers et al., 2005; Su et al., 2003; Grenyer et al., 2007), perhaps
suggesting that the dosage, more than the type of treatment, might
influence patients’ response. Our present work shows that treat-
ment with either DHA or EPA has a positive effect on neurogenesis,
with DHA also decreasing the production of the neurotoxic quino-
linic acid. In contrast, in our previous study we demonstrated an
overall anti-inflammatory pattern for EPA, but a mostly pro-
inflammatory one for DHA upon co-treatment with IL-1b. Interest-
ingly, both those effects were associated with a corresponding
decrease in the NF-kB activation caused by IL-1b alone (Horowitz
et al., 2015). In addition, we have also seen that EPA, but not
DHA, can revert the damage caused by oxidative stress in our
human hippocampal cell model. We have no indication about the
overall status of the patients evaluated in clinical studies (includ-
ing neurogenesis, oxidative stress, inflammation or regulation in
the kynurenine pathway), so a possible overlap or the prominence
of any of the possible dysregulations cannot be excluded. Consider-
ing that all clinical studies involved supplementation, it is also pos-
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Fig. 5. Antidepressants and x-3 fatty acids modulate IL-1b-induced changes to the expression of enzymes of the kynurenine pathway. Co-treatment of cells with IL-1b andx-
3 fatty acids or antidepressants decreased the expression of IDO (a). Co-treatment with DHA, sertraline or venlafaxine decreased expression of KMO (b). Co-treatment with
DHA upregulated KMO production (c). Co-incubation with sertraline or venlafaxine decreased the upregulation of ACMSD (d); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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sible that EPA and DHA have differential interactions with various
antidepressant drugs. Studies with individual combinations would
therefore be of interest.
5. Conclusions
In summary, our observations indicate that venlafaxine, sertra-
line, EPA and DHA show protective effects against the detrimental
influence of IL-1b on human hippocampal neurogenesis. We also
find that one potential explanation for these effects is that these
compounds may be involved in regulating IL-1b signaling by mod-
ulation of the kynurenine pathway, as DHA and sertraline reduce
levels of the neurotoxic quinolinic acid increased by the cytokine,
with a similar trend observed for EPA and venlafaxine. An
increased understanding of the molecular mechanisms underlying
these effects may allow for a more effective future personalization
of antidepressant use.
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